HemeRetic
Primary Site | Histology | Behavior | Schema Discriminator 1 |
---|---|---|---|
C000-C440, C442-C689, C691-C694, C698-C699, C739-C749, C750, C754-C759, C760-C809 | 9591 | <Any value> | 1, 2 |
C700-C729, C751-C753 | 9591 | 3 | 1, 2 |
C000-C699, C739-C750, C754-C809 | 9724, 9727, 9740-9742, 9762-9809, 9811-9820, 9831-9920, 9931-9992 | <Any value> | <Any value> |
C700-C729, C751-C753 | 9724, 9727, 9740-9742, 9762-9809, 9811-9820, 9831-9920, 9931-9992 | 3 | <Any value> |
C000-C699, C739-C750, C754-C809 | 9751, 9755-9759 | <Any value> | <Any value> |
C000-C440, C442-C689, C691-C694, C698-C699, C739-C750, C754-C809 | 9930 | <Any value> | <Any value> |
C700-C729, C751-C753 | 9930 | 3 | <Any value> |
Notes
9724, 9727, 9740-9742, 9762-9809, 9811-9820, 9831-9920, 9931-9992
9591 and Schema Discriminator 1: 1, 2 (C000-C440, C442-C689, C691-C694, C698-C809)
9751, 9755-9759 (C000-C699, C739-C750, C754-C809)
9930 (C000-C440, C442-C689, C691-C694, C698-C809)
Note 1: The following sources were used in the development of this schema
- SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)
- SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)
- Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx
- Chapter 83 Leukemia, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.
Note 2: See the following schemas for the listed histologies
- 9591 and Schema Discriminator 1: 3, 9 (C000-C440, C442-C689, C691-C694, C698-C809): Lymphoma
- 9751, 9755-9759 (C700, C710-C719): Brain
- 9751, 9755-9759 (C701, C709, C720-C725, C728-C729): CNS Other
- 9751, 9755-9759 (C751-C753): Intracranial Gland
- 9930 (C441, C690, C695-C696): Lymphoma Ocular Adnexa
Note 3: Summary Stage is the only applicable staging system for this site/histology/schema.
Note 4: M-See list of specific histologies below, effective for cases diagnosed 2010 and forward. All primary sites (C000-C809) are included unless otherwise specified.
Note 5: Schema includes the preferred terms based on the 2017 WHO Classification of Haematopoietic and Lymphoid Tissues
9591 Splenic B-cell lymphoma/leukemia, unclassifiable (except C441, C690, C695-C696)
9724 Systemic EBV-positive T-cell lymphoma of childhood
9727 Blastic plasmacytoid dendritic cell neoplasm
9740 Mast cell sarcoma
9741 Systemic mastocytosis with an associated hematological neoplasm
9742 Mast cell leukemia
9751 Langerhans cell histiocytosis, disseminated (except C700-C729, C751-C753)
9755 Histiocytic sarcoma (except C700-C729, C751-C753)
9756 Langerhans cell sarcoma (except C700-C729, C751-C753)
9757 Interdigitating dendritic cell sarcoma (except C700-C729, C751-C753)
9758 Follicular dendritic cell sarcoma (except C700-C729, C751-C753)
9759 Fibroblastic reticular cell tumor (except C700-C729, C751-C753)
9762 Heavy chain diseases
9800 Leukemia, NOS
9801 Acute undifferentiated leukemia
9806 Mixed-phenotype acute leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
9807 Mixed-phenotype acute leukemia with t(v;11q23.3); KMT2A-rearranged
9808 Mixed -phenotype acute leukemia, B/myeloid, NOS
9809 Mixed-phenotype acute leukemia, T/myeloid, NOS
9811 B-lymphoblastic leukemia/lymphoma, NOS
9812 B-lymphoblastic leukemia/lymphoma with t(9;22))q34.1;q11.2); BCR-ABL1
9813 B-lymphoblastic leukemia/lymphoma with t(v;11q23.3); KMT2A-rearranged
9814 B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1
9815 B-lymphoblastic/lymphoma with hyperdiploidy
9816 B-lymphoblastic/lymphoma with hypodiploidy (hypodiploid ALL)
9817 B-lymphoblastic/lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3
9818 B-lymphoblastic/lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1
9820 Lymphoid leukemia, NOS
9831 T-cell large granular lymphocytic leukemia
9832 Prolymphocytic leukemia, NOS
9833 B-cell prolymphocytic leukemia
9834 T-cell prolymphocytic leukemia
9837 T-lymphoblastic leukemia/lymphoma
9840 Pure erythroid leukemia
9860 Myeloid leukemia, NOS
9861 Acute myeloid leukemia, NOS
9863 Chronic myeloid leukemia
9865 Acute myeloid leukemia with t(6;9)(p23;q34.1); DEK-NUP214
9866 Acute promyelocytic leukemia with PML-RARA
9867 Acute myelomonocytic leukemia
9869 Acute myeloid leukemia with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26;2); RBM15-MKL1
9870 Acute basophilic leukemia
9871 Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
9872 Acute myeloid leukemia, minimal differentiation
9873 Acute myeloid leukemia without maturation
9874 Acute myeloid leukemia with maturation
9875 Chronic myeloid leukemia, BCR-ABL1-positive
9876 Atypical chronic myeloid leukemia BCR-ABL1-negative
9891 Acute monoblastic and monocytic leukemia
9895 Acute myeloid leukemia with myelodysplasia-related changes
9896 Acute myeloid leukemia with t(8;21)(q22;q22.1), RUNX1-RUNX1T1
9897 Acute myeloid leukemia with t(9;11)(p21.3;q23.3); KMT2A-MLLT3
9898 Myeloid leukemia associated with Down Syndrome
9910 Acute megakaryoblastic leukemia
9911 Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1
9920 Therapy-related myeloid neoplasms
9930 Myeloid sarcoma (except C441, C690, C695-C696)
9931 Acute panmyelosis with myelofibrosis
9940 Hairy cell leukemia
9945 Chronic myelomonocytic leukemia, NOS
9946 Juvenile myelomonocytic leukemia
9948 Aggressive NK-cell leukemia
9950 Polycythemia vera
9961 Primary myelofibrosis
9962 Essential thrombocythemia
9963 Chronic neutrophilic leukemia
9964 Chronic eosinophilic leukemia, NOS
9965 Myeloid/lymphoid neoplasms with PDGFRA rearrangement
9966 Myeloid/lymphoid neoplasm with PDGFRB rearrangement
9967 Myeloid/lymphoid neoplasm with FGFR1 rearrangement
9971 Polymorphic PTLD
9975 Myelodysplastic/myeloproliferative neoplasm, unclassifiable
9980 Myelodysplastic syndrome with single lineage dysplasia
9982 Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia
9983 Myelodysplastic syndrome with excess blasts
9985 Myelodysplastic syndrome with multilineage dysplasia
9986 Myelodysplastic syndrome with isolated del(5q)
9989 Myelodysplastic syndrome, unclassifiable
9991 Refractory neutropenia
9992 Refractory thrombocytopenia
Data Items
Name | Default Value | Used for Staging | NAACCR Item | Required By | Metadata |
---|---|---|---|---|---|
Year of Diagnosis | <BLANK> | No | NAACCR #390 | None | |
Primary Site | <BLANK> | Yes | NAACCR #400 | None | |
Histology | <BLANK> | Yes | NAACCR #522 | None | |
Behavior | <BLANK> | Yes | NAACCR #523 | None | |
Schema Discriminator 1 | <BLANK> | Yes | NAACCR #3926 | All | SSDI |
Age at Diagnosis | <BLANK> | Yes | NAACCR #230 | None | |
Tumor Size Clinical | <BLANK> | No | NAACCR #752 | None | |
Tumor Size Pathological | <BLANK> | No | NAACCR #754 | None | |
Tumor Size Summary | 999 | No | NAACCR #756 | None | |
Regional Nodes Positive | 99 | No | NAACCR #820 | None | |
Regional Nodes Examined | 99 | No | NAACCR #830 | None | |
EOD Primary Tumor | 999 | Yes | NAACCR #772 | None | |
EOD Regional Nodes | 888 | Yes | NAACCR #774 | None | |
EOD Mets | 88 | Yes | NAACCR #776 | None | |
SS2018 | <BLANK> | No | NAACCR #764 | None | |
Grade Clinical | 8 | No | NAACCR #3843 | CCCR/Canada COC NPCR SEER |
SSDI |
Grade Pathological | 8 | No | NAACCR #3844 | CCCR/Canada COC NPCR SEER |
SSDI |
Grade Post Therapy | <BLANK> | No | NAACCR #3845 | CCCR/Canada COC NPCR SEER |
SSDI |
JAK2 | 8 | No | NAACCR #3862 | COC SEER |
SSDI |